Crucial Vote Looms for CureVac Shareholders as BioNTech Acquisition Nears Finish Line
Published on 11/04/2025 at 05:17 | Redaktion boerse-global.de
The proposed acquisition of CureVac by BioNTech is accelerating toward its final stages. CureVac investors face a pivotal decision on November 25, when they will cast their votes on the $1.25 billion merger agreement. This critical shareholder meeting approaches as recent financial disclosures from the acquiring company introduce fresh considerations for the deal.
BioNTech presented its third-quarter financial results, reporting substantial revenues of approximately €1.5 billion. Despite this significant income, the company registered a net loss of €28.7 million. Part of this deficit stems from resolving contractual disputes with GSK related to a licensing agreement that originally involved CureVac. This financial entanglement highlights the already complex relationship between the two German biotech firms.
Notably, Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
